Veeva Vault CRM Selected by Regeneron

Rhea-AI Summary

Veeva Systems (NYSE: VEEV) announced that Regeneron Pharmaceuticals has committed to deploy Veeva Vault CRM globally across its commercial organization. Regeneron plans to use the AI-powered platform to generate Commercial Evidence from field engagement, identify barriers to treatment adoption, and support faster, data-informed commercial decisions.

Vault CRM, part of the Vault CRM Suite, includes the Agentic Call Report, which turns each field interaction into structured insights while addressing prior issues with dropdown-based data and compliance concerns. The announcement extends the long-standing strategic partnership between Veeva and Regeneron.

Positive

• Global Vault CRM commitment from Regeneron expands strategic partnership and broadens Veeva’s footprint with a major biopharma customer
• AI-powered Agentic Call Report adoption positions Veeva technology at the core of Regeneron’s commercial evidence generation and field engagement

Negative

• None.

Market Context

Veeva’s August 11 Lilly announcement was followed by 0.81% over 24 hours, providing a directly compa...

Analysis

Veeva’s August 11 Lilly announcement was followed by 0.81% over 24 hours, providing a directly comparable customer-commitment reference. Regeneron’s selection broadens that record; recent insider activity was Net Selling, a separate monitoring risk.

Key Figures

Announcement date: Aug. 25, 2026 Customers: more than 1,500 customers

2 metrics

Announcement date Aug. 25, 2026 Veeva announcement

Customers more than 1,500 customers Veeva company description

Historical Context

5 past events · Latest: Aug 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Vault CRM commitment	Positive	+0.8%	Eli Lilly committed to deploy Vault CRM globally.
Aug 05	Earnings date notice	Neutral	+2.0%	Company announced the fiscal 2027 second-quarter results date.
Jun 25	EHS application launch	Positive	-2.0%	Veeva introduced a new environmental, health, and safety application.
Jun 23	Copli acquisition	Positive	+4.3%	Veeva acquired Copli and launched Falcon MLR.
Jun 09	Safety Suite adoption	Positive	+0.3%	UCB unified global pharmacovigilance operations on Safety Suite.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Three positive company announcements aligned with positive reactions, while one positive product announcement diverged; the scheduling news also had a positive move.

Key Terms

forward-looking statements, form 10-q

2 terms

forward-looking statements regulatory

"This release contains forward-looking statements regarding Veeva's products"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

form 10-q regulatory

"disclosed in our filing on Form 10-Q for the fiscal year ended April 30"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence

PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring their medicines can reach eligible patients in need. 

"We are pleased to expand our strategic partnership with Veeva by moving to Vault CRM, which will give our commercial teams a more connected platform and help them get faster access to the information they need for efficient decision-making," said Ryan Steinberger, executive vice president and chief digital and technology officer at Regeneron.

"Regeneron uses the power of science to invent, develop, and commercialize life-transforming medicines for people with serious diseases," said Matt Farrell, president, commercial strategy at Veeva. "We are honored to extend our strategic partnership with Regeneron to include Veeva Vault CRM as they continue to deliver important new medicines to people in need."

Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution. With the Agentic Call Report in Vault CRM, every field interaction becomes a source of Commercial Evidence, capturing insights previously lost to dropdowns and compliance concerns.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Maria Scurry Veeva Systems maria.scurry@veeva.com	Meera Lakhani-Patel Veeva Systems, Europe meera.lakhani-patel@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-vault-crm-selected-by-regeneron-302858870.html

SOURCE Veeva Systems

FAQ

What did Regeneron select Veeva Vault CRM for in August 2026 (VEEV)?

Regeneron selected Veeva Vault CRM globally to support its commercial organization. According to Veeva, Regeneron plans to use the AI-powered CRM to generate Commercial Evidence, uncover barriers to treatment adoption, and help ensure its medicines reach eligible patients.

How will Veeva Vault CRM support Regeneron’s commercial teams according to Veeva (VEEV)?

Veeva says Vault CRM will give Regeneron’s commercial teams a more connected platform and faster access to needed information. This is expected to support efficient decision-making and improve how field engagement data is captured and turned into actionable Commercial Evidence.

What is the Agentic Call Report in Veeva Vault CRM mentioned in the Regeneron deal?

The Agentic Call Report in Vault CRM turns each field interaction into a source of Commercial Evidence. According to Veeva, it captures insights that were previously lost to dropdown-based entry and compliance concerns, strengthening the technology foundation for commercial execution in life sciences.

How does the Regeneron win fit into Veeva Systems’ broader customer base (NYSE: VEEV)?

According to Veeva, the Regeneron commitment extends an existing strategic partnership and adds to a base of more than 1,500 customers. These customers range from large global pharmaceutical companies to emerging biotechs using Veeva’s industry cloud for life sciences.

What type of technology does Veeva provide to life sciences companies like Regeneron?

Veeva provides an industry cloud for life sciences, including applications, AI agents, data, and consulting services. According to Veeva, these offerings form a technology foundation for commercial execution and are designed to support innovation, product excellence, and customer success in the sector.

Does the Veeva-Regeneron Vault CRM announcement include financial guidance for VEEV shareholders?

The announcement does not provide specific financial terms or guidance related to the Regeneron CRM commitment. According to Veeva, the release contains forward-looking statements and refers investors to its Form 10-Q for the fiscal year ended April 30, 2026, and subsequent SEC filings for risk factors.